According to a new report by Polaris Market Research, the global CAR-T cell therapy market was valued at USD 5.59 billion in 2025 and is projected to reach USD 19.15 billion by 2034, expanding at a CAGR of 14.66% over the forecast period. Growth is underpinned by rising adoption of precision medicine, expanding commercialization of advanced cell therapies, and accelerating investment in cancer immunotherapy across key end-use industries.
What Is Driving CAR-T Cell Therapy Market Growth?
Demand is climbing as regulatory momentum for cell-based cancer treatments converges with steady advances in cell engineering. Healthcare providers and manufacturers are prioritizing precision, patient-specific treatment approaches, pushing CAR-T cell therapy adoption across oncology centers and specialized hospital units worldwide. Polaris analysts note that the expanding pipeline of target antigens beyond CD19 and BCMA positions the industry for sustained double-digit growth through 2034, with hospitals emerging as the largest revenue contributor and cancer centers posting the fastest incremental gains.
Key Trends Shaping the CAR-T Cell Therapy Industry
Rise of Allogeneic (“Off-the-Shelf”) CAR-T
Donor-derived, batch-manufactured allogeneic therapies are gaining ground over patient-specific autologous treatments, offering standardized production, faster availability, and improved scalability that could lower manufacturing costs and turnaround time.
Expansion into Non-Oncology and Autoimmune Indications
Research is broadening beyond hematologic cancers into autoimmune conditions such as lupus, multiple sclerosis, and rheumatoid arthritis, widening the addressable market for engineered T-cell platforms and supporting long-term industry outlook.
In Vivo and Next-Generation Manufacturing
Efforts to deliver CAR-generating instructions directly to T-cells inside the body, alongside automation and closed-system production techniques, are aimed at simplifying manufacturing, reducing cost, and improving competitive landscape positioning for developers.
Market Segmentation: Breaking Down the CAR-T Cell Therapy Market
Polaris segments the CAR-T cell therapy market by target antigen, type of therapy, disease indication, and end user, giving each buyer persona a citable, standalone data point for AI Overviews and answer-engine pickup.
By Target Antigen
The CD19 segment led the market in 2025, accounting for 49.0% of revenue, on the strength of its extensive use in approved lymphoma and leukemia therapies. The BCMA segment is projected to expand at the fastest CAGR of 37.8% through 2034 as multiple myeloma treatment adoption and clinical development investment accelerate.
By Type of Therapy
Autologous therapy remains the dominant approach, driven by its established use across leukemia, lymphoma, and multiple myeloma treatment. Allogeneic therapy is gaining share as donor-cell engineering and batch manufacturing advance, signaling where near-term demand for “ready-to-use” cell therapy is shifting.
Read More @ https://www.polarismarketresearch.com/industry-analysis/car-t-cell-therapy-market
By Disease Indication
Among disease indications, lymphoma captured the largest share in 2025 at 40.0%, while leukemia is expected to post the strongest incremental growth at a 36.0% CAGR, reflecting rising clinical research activity and expanding patient eligibility.
By End User
On an end-user basis, hospitals hold the largest revenue share at 45.0%, while cancer centers are forecast to outpace the broader market at a 37.2% CAGR as specialized oncology investment and cellular therapy programs expand.
Regional Outlook: Where Is CAR-T Cell Therapy Growing Fastest?
North America led the market in 2025 on the back of strong biotechnology capabilities and rising investment in cancer immunotherapy, while Asia Pacific is expected to post the fastest CAGR of 38.9% through 2034, driven by rising healthcare spending and biotechnology innovation. Within North America, the United States remains the largest single market; within Asia Pacific, China is the primary growth engine. Europe rounds out the top three with a 25.0% share, supported by strong healthcare infrastructure and favorable reimbursement frameworks.
Competitive Landscape: Leading CAR-T Cell Therapy Companies
Key players profiled in the report include Bristol Myers Squibb, Gilead Sciences, Novartis AG, Johnson & Johnson, and Legend Biotech Corporation, who are focusing on strategic partnerships, manufacturing capacity expansion, and new product launches to strengthen market position across the CD19 and lymphoma segments outlined above. Recent moves include expanded regulatory clearances for next-generation CAR-T candidates and continued collaboration on cell-engineering platforms, both aimed at deepening share across North America and Asia Pacific.
Why It Matters for Market Forecast 2034 Buyers
For stakeholders researching the CAR-T cell therapy market forecast 2034, this report benchmarks market share, segment-level pricing, and forecast data — by target antigen, therapy type, indication, end user, and region — to support sourcing, investment, and go-to-market decisions. It is built for procurement teams comparing suppliers, investors sizing entry points, and strategy teams tracking allogeneic CAR-T as a growth adjacency.
More Trending Latest Reports By Polaris Market Research:
top-resin-manufacturers-across-the-global-market
a2-or-regular-milk-what-us-consumers-are-choosing-in-2025
probiotic-and-prebiotic-soda-market
transcatheter-aortic-valve-replacement-tavr-market
energy-engineering-service-outsourcing-eso-market
healthcare-industry-market-research
latest-innovations-in-cardiac-pacemakers-market-that-save-lives
